A bacteriocin mutant AM-1 and its application

By mutation of the amino acid sequence of the bipeptide bacteriocin Crustoricin X, the bacteriocin mutant with higher antibacterial activity was obtained, which solved the problems of low antibacterial activity of existing bacteriocin and difficulty in industrial preparation, and achieved high efficiency and ease of Prepared food anticorrosion effect.

CN117986324BActive Publication Date: 2024-11-05NORTHWEST A & F UNIV +1
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202311794554.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-12-25
Publication Date
2024-11-05
Estimated Expiration
2043-12-25

AI Technical Summary

Technical Problem

The existing bacterial bacterial activity is low, requires high dosage, and there are problems such as difficulty in isolation and purification, complicated extraction steps, and low yield in industrial preparation, making it difficult to meet the green preservative needs of food.

Method used

By mutation of the amino acid sequence of the bipeptide bacteriocin Crustoricin X, the bacterial mutant AM-1 is obtained. The amino acids such as alanine, glutamine, glycine at specific sites in the amino acid sequence are mutated into tryptophan, Lai Amino acid, etc., improve its antibacterial and bactericidal activity against a variety of food-borne pathogenic bacteria, and simplifies the preparation process through conventional polypeptide solid-phase synthesis.

Benefits of technology

The bacterial mutant AM-1 significantly improves the antibacterial and bactericidal effect on a variety of foodborne pathogens at a lower dosage. It has a simple structure and is easy to synthesize. It can effectively inhibit and kill a variety of pathogenic bacteria and reduce the tolerance of pathogens. Medicinal properties, suitable for food preservatives and feed additives and other products.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117986324B_ABST
    Figure CN117986324B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of microbial technology, and specifically relates to a bacteriocin mutant AM‑1 and its application. The amino acid sequence of the bacteriocin mutant AM‑1 is shown in SEQ ID NO.1. The bacteriocin mutant AM‑1 is obtained by mutating the polypeptide whose amino acid sequence is shown in SEQ ID NO.2 in the dipeptide bacteriocin Crustoricin X. Compared with the polypeptide, the bacteriocin mutant AM‑1 has higher antibacterial activity against a variety of foodborne pathogens, and also has high bactericidal activity against a variety of foodborne pathogens; the bacteriocin mutant AM‑1 has a simple structure, can be synthesized by conventional polypeptide solid phase synthesis method, is easy to produce and prepare, and is expected to be produced and made into antibacterial and / or antiseptic products on an industrial scale.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and in particular relates to a bacteriocin mutant AM-1 and application thereof. Background Art

[0002] In order to solve the problem of high contamination rate of foodborne pathogenic microorganisms, the existing technology usually adopts the method of using food additives such as preservatives. However, most of these food additives are artificially synthesized chemical preservatives or antibiotics, which are inconsistent with consumers' expectations of pursuing natural and healthy food, and often make consumers stay away from them.

[0003] Bacteriocins, as a natural antibacterial substance, are an ideal substitute for chemical preservatives and antibiotics and can be used for green preservation of food. However, not all bacteriocins have excellent antibacterial activity, and bacteriocins with low antibacterial activity need to be added at a higher amount to work, which undoubtedly puts forward requirements for their industrial preparation. However, the natural resources of microorganisms are limited, and bacteriocins have problems such as difficulty in separation and purification, cumbersome extraction steps, and low yield during industrial preparation due to their small molecular weight, which restricts the widespread use of bacteriocins. Artificial design and modification of bacteriocins is a fast and effective way to change the original activity, and has become an important part of bacteriocin development. However, bacteriocins may not necessarily produce ideal antibacterial activity after artificial design and modification, and may still be difficult to prepare. Summary of the invention

[0004] In view of the above problems, the present invention provides a bacteriocin mutant AM-1 and its application. Experimental studies have found that the bacteriocin mutant AM-1 provided by the present invention has high antibacterial activity against common foodborne pathogens, and has a simple structure and is easy to prepare, and is expected to be produced on an industrial scale and used in antibacterial and / or antiseptic products.

[0005] In order to achieve the above-mentioned purpose of the invention, the embodiment of the present invention adopts the following technical solutions:

[0006] In a first aspect, the present invention provides a bacteriocin mutant AM-1, whose amino acid sequence is shown in SEQ ID NO.1.

[0007] The bacteriocin mutant AM-1 is obtained by mutating the polypeptide of the amino acid sequence of the dipeptide bacteriocin Crustoricin X as shown in SEQ ID NO.2. The specific mutation method is: mutating the alanine at position 1 to tryptophan, the glutamine at position 4 to lysine, the glycine at position 5 to lysine, the glycine at position 7 to tryptophan, the aspartic acid at position 11 to arginine, the glutamine at position 12 to lysine, and the histidine at position 13 to lysine in the polypeptide of the dipeptide bacteriocin Crustoricin X as shown in SEQ ID NO.2.

[0008] Compared with the polypeptide with the amino acid sequence shown in SEQ ID NO.2 in the dipeptide bacteriocin Crustoricin X, the bacteriocin mutant AM-1 has higher antibacterial activity against a variety of foodborne pathogens and can produce excellent antibacterial effects at a lower dosage. In addition, the bacteriocin mutant AM-1 also has high bactericidal activity against a variety of foodborne pathogens and can effectively reduce the number of foodborne pathogens.

[0009] The bacteriocin mutant AM-1 has a simple structure, can be synthesized by a conventional polypeptide solid phase synthesis method, and is easy to produce and prepare.

[0010] In a second aspect, the present invention provides the use of the bacteriocin mutant AM-1 in the preparation of antibacterial and / or antiseptic products.

[0011] The bacteriocin mutant AM-1 has a wide antibacterial spectrum, and has high inhibitory and killing activities against Gram-positive bacteria and Gram-negative bacteria, so it can be used to prepare antibacterial and / or preservative products that inhibit the above-mentioned pathogenic bacteria.

[0012] In combination with the second aspect, the antibacterial and / or preservative product is a product that inhibits and / or kills any one or more pathogenic bacteria among Escherichia coli, Staphylococcus aureus, Bacillus cereus, Enterobacter sakazakii, Salmonella typhimurium, Klebsiella pneumoniae, Enterococcus faecalis, Micrococcus luteus and Listeria monocytogenes.

[0013] In a third aspect, the present invention further provides an antibacterial and / or preservative product, the ingredients of which include the above-mentioned bacteriocin mutant AM-1.

[0014] In combination with the third aspect, the antibacterial and / or preservative products include food preservatives, feed additives and antibacterial drugs.

[0015] The beneficial effects of the present invention are as follows: the bacteriocin mutant AM-1 provided by the present invention has a simple structure, can be synthesized by conventional solid phase synthesis and other methods, and is easy to prepare. The bacteriocin mutant AM-1 can effectively inhibit and kill Gram-positive bacteria such as Staphylococcus aureus, Bacillus cereus, Enterococcus faecium, Listeria monocytogenes, and Gram-negative bacteria such as Enterobacter sakazakii, Salmonella typhimurium, Klebsiella pneumoniae, Micrococcus luteus, and Escherichia coli, and its antibacterial and bactericidal activities are not only significantly higher than those of the dipeptide bacteriocin Crustoricin X, but also significantly higher than other mutants obtained by performing other mutations on the polypeptide shown in SEQ ID NO.2 of the amino acid sequence of the dipeptide bacteriocin Crustoricin X. In addition, the bacteriocin mutant AM-1 can also destroy the cell membrane and cell morphology of pathogenic bacteria, thereby reducing the drug resistance of pathogenic bacteria. Therefore, the bacteriocin mutant AM-1 provided by the present invention can be used to prepare antibacterial and / or antiseptic products such as food preservatives, feed additives, and antibacterial drugs, and has broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 The test results of the effect of AM-1 on the cell membrane integrity of Escherichia coli ATCC 25922 in Example 4;

[0017] Figure 2 The test results of the effect of AM-1 on the cell morphology of Escherichia coli ATCC 25922 in Example 5 are shown. DETAILED DESCRIPTION

[0018] In order to make the purpose, technical scheme and advantages of the present invention clearer, the present invention is further described in detail below in conjunction with specific embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work fall within the scope of protection of the present invention.

[0019] Bacteriocins, as a natural antibacterial substance, are ideal substitutes for chemical preservatives and antibiotics and can be used for green food preservation. However, not all bacteriocins have excellent antibacterial activity, and bacteriocins with low antibacterial activity need to be added in higher amounts to work, which requires easy industrial preparation. However, the natural resources of microorganisms are limited, and bacteriocins have small molecular weights, so they are difficult to separate and purify, have complicated extraction steps, and have low yields during industrial preparation.

[0020] To address this problem, the inventors artificially designed and modified natural bacteriocin and obtained a bacteriocin mutant AM-1 with an amino acid sequence as shown in SEQ ID NO. 1. After testing, the bacteriocin mutant AM-1 has a wider antibacterial spectrum and has higher inhibitory activity against a variety of Gram-positive and Gram-negative bacteria than the dipeptide bacteriocin Crustoricin X.

[0021] Based on the antibacterial and bactericidal effects of the bacteriocin mutant AM-1, the embodiments of the present invention provide the use of the bacteriocin mutant AM-1 in the preparation of antibacterial and / or preservative products, and the corresponding products include but are not limited to food preservatives, feed additives, antibacterial drugs, etc.

[0022] The embodiments of the present invention also provide an antibacterial and / or antiseptic product containing the bacteriocin mutant AM-1.

[0023] The scheme of the present invention is described below through specific embodiments.

[0024] Unless otherwise specified, the technical means used in the following examples are conventional means well known to those skilled in the art; the materials, reagents, etc. used in the following examples can be obtained from commercial channels.

[0025] Example 1

[0026] This example provides a bacteriocin mutant AM-1 having an amino acid sequence as shown in SEQ ID NO.1 and a process for obtaining the same.

[0027] The bacteriocin mutant AM-1 is obtained by mutating the alanine at the 1st position of the bacteriocin Crustoricin X in the dipeptide bacteriocin Crustoricin X to tryptophan, the glutamine at the 4th position to lysine, the glycine at the 5th position to lysine, the glycine at the 7th position to tryptophan, the aspartic acid at the 11th position to arginine, the glutamine at the 12th position to lysine and the histidine at the 13th position to lysine, so as to obtain the bacteriocin mutant AM-1 with the amino acid sequence as shown in SEQ ID NO.1.

[0028] The bacteriocin mutant AM-1 used in the following Examples 2 to 5 was prepared by Qiangyao Biotechnology Co., Ltd. (Shanghai) through conventional solid phase synthesis, with a purity of >90% (the content of the synthesized target peptide in the total peptide).

[0029] Example 2

[0030] This example provides the antibacterial activity of the bacteriocin mutant AM-1 having an amino acid sequence as shown in SEQ ID NO.1 against a variety of foodborne pathogens.

[0031] Using 5% DMSO as diluent, a series of gradient AM-1 solutions (8, 16, 31, 62, 125, 250, 500, 1000, 2000 μM) were prepared by double dilution method. Indicator bacteria such as Staphylococcus aureus, Escherichia coli, and Listeria monocytogenes were cultured overnight and diluted with LB medium to a final bacterial density of 5.0×10 5 CFU / mL. 10 μL of diluted antibacterial peptides of various concentrations were added to a 96-well plate containing 90 μL of bacterial solution, and a growth control and a sterile control were set up. The plates were cultured at 37°C for 20 h, and the minimum inhibitory concentration (MIC) was determined according to the turbidity of the bacterial solution in the wells. The results are shown in Table 1.

[0032] Table 1 Determination of minimum inhibitory concentrations for various foodborne pathogens

[0033]

[0034] Example 3

[0035] This example provides the bacteriocin mutant AM-1 having an amino acid sequence as shown in SEQ ID NO.1 and its bactericidal activity against a variety of foodborne pathogens.

[0036] Using 5% DMSO as diluent, a series of gradient AM-1 solutions (8, 16, 31, 62, 125, 250, 500, 1000, 2000 μM) were prepared by double dilution method. Indicator bacteria such as Staphylococcus aureus, Escherichia coli, and Listeria monocytogenes were cultured overnight and diluted with LB medium to a final bacterial density of 5.0×10 5 CFU / mL. Take 10μL of the diluted antibacterial peptides of each concentration and add them to a 96-well plate containing 90μL of bacterial solution, and set up a growth control and a sterile control, and culture at 37℃ for 20h. Take 10μL of the content without obvious turbidity, spread it on the LB agar plate, culture at 37℃ for 18-24h, and observe whether there are colonies growing on the culture medium. The minimum concentration corresponding to the culture medium without colony growth is the minimum bactericidal concentration (MBC) of the bacteriocin. The results are shown in Table 2.

[0037] Table 2 Determination of minimum bactericidal concentration for various foodborne pathogens

[0038]

[0039] Example 4

[0040] This example provides the effect of the bacteriocin mutant AM-1, whose amino acid sequence is shown in SEQ ID NO.1, on the cell membrane integrity of pathogenic bacteria.

[0041] The indicator bacteria (Escherichia coli ATCC 25922) cultured to the logarithmic phase were centrifuged at 8000×g at 4°C for 5 min, and the cells were collected and resuspended in LB medium to a concentration of 10 8 AM-1 was added to the bacterial suspension to a final concentration of 0, 1, 2, and 4×MIC, and the culture was continued at 37°C for 1 h. The bacteria were collected by centrifugation at 8000×g for 5 min at 4°C, and washed three times with 0.01M PBS (pH 7.2). The bacteria were resuspended to 10 7 CFU / mL. 10 μL PI dye solution was added to 190 μL bacterial suspension and incubated at room temperature in the dark for 30 min. PI absorption of each treatment was measured using a FACS Calibur flow cytometer (Becton Dickinson, USA).

[0042] Effects of AM-1 on the integrity of Escherichia coli cell membrane Figure 1 As shown. Figure 1 It can be seen that AM-1 has different degrees of destructive effect on the cell membrane of Escherichia coli, and the destructive effect increases with the increase of treatment concentration.

[0043] Example 5

[0044] This example provides the effect of the bacteriocin mutant AM-1, whose amino acid sequence is shown in SEQ ID NO.1, on the cell morphology of pathogenic bacteria.

[0045] The indicator bacteria (Escherichia coli ATCC 25922) cultured to the logarithmic phase were centrifuged at 8000×g at 4°C for 5 min, and the cells were collected and resuspended in LB medium to a concentration of 10 8 CFU / mL. AM-1 was added to the bacterial suspension to a final concentration of 4×MIC, and the culture was continued at 37°C for 1 hour. The bacteria were washed three times with sterile 0.01M PBS (pH 7.2) to remove residual peptides. The bacteria were fixed with 2.5% glutaraldehyde overnight, and the indicator bacteria were washed with PBS for 2-3 times, each time for 10 minutes. Subsequently, different concentrations of ethanol were used for gradient dehydration, and dehydration was performed for 10 minutes at each concentration. After replacement with isoamyl acetate for 10 minutes, the bacteria were placed in a fully automatic critical point dryer for dehydration and drying, sprayed with gold powder, and the bacterial morphology was observed on a high resolution Nova NanoSEM450 scanning electron microscope (FEI, USA).

[0046] Effects of AM-1 on the integrity of Escherichia coli cell membrane Figure 2 As shown. Figure 2 It can be seen that after AM-1 treatment, E. coli cells showed visible pore formation and cell membrane wrinkles.

[0047] Comparative Example 1

[0048] The present comparative example provides a bacteriocin mutant AM-2, whose amino acid sequence is: AFAQGIGDWIDQDI, which is obtained by changing the tryptophan at the 3rd position of the bacteriocin Crustoricin X, whose amino acid sequence is shown in SEQ ID NO.2, to alanine, the arginine at the 8th position to aspartic acid, and the histidine at the 13th position to aspartic acid.

[0049] After testing, the net charge of the bacteriocin mutant AM-2 was -3, which is not conducive to electrostatic attraction with negatively charged lipids on the bacterial surface, and therefore it is difficult to aggregate on the bacterial membrane surface to exert an antibacterial effect.

[0050] SOPMA predicted the secondary structure of the bacteriocin mutant AM-2 protein: the overall structure is an irregular curled structure, which is not conducive to bacterial membrane perforation, making it difficult to exert antibacterial activity.

[0051] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modification, equivalent substitution or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A bacteriocin mutant AM-1, characterized in that The amino acid sequence of the bacteriocin mutant AM-1 is shown in SEQ ID NO.

1.

2. Use of the bacteriocin mutant AM-1 according to claim 1 in the preparation of antibacterial and / or antiseptic products, characterized in that: The antibacterial and / or preservative product is a product that inhibits and / or kills any one or more pathogenic bacteria among Escherichia coli, Staphylococcus aureus, Bacillus cereus, Enterobacter sakazakii, Salmonella typhimurium, Klebsiella pneumoniae, Enterococcus faecium, Micrococcus luteus and Listeria monocytogenes.

3. An antibacterial and / or antiseptic product, characterized in that: Its components include the bacteriocin mutant AM-1 described in claim 1.

4. The antibacterial and / or antiseptic product according to claim 3, characterized in that: The antimicrobial and / or antiseptic products include food preservatives, feed additives and antimicrobial drugs.

Citation Information

Patent Citations

  • Leader peptide-free bacteriocin subticin A1 for resisting various food-borne pathogenic bacteria and application

    CN116041453A

  • Polypeptide, bipeptide bacteriocin Crustoriin X containing polypeptide and application of bipeptide bacteriocin X

    CN116143878A

  • Full-biosynthesis method of cyclic bacteriocin AS-48

    CN117088946A

  • Bacteriocin polypeptides, nucleic acids encoding same, and methods of use thereof

    WO2023235682A1